Physician profile
Katelyn Mitchell
NPI 1003471699
$776.31
in general payments reported to CMS, 2019-2025
15 companies · $26.30 in 2025
The $26.30 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $184 · 2021: $42.10 · 2023: $346 · 2024: $44.42 · 2025: $26.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $180.15 | 2020-2023 | |
| Allergan, INC. | $120.77 | 2019 | |
| Inspire Medical Systems, INC. | $83.14 | 2023 | Inspire |
| Boston Scientific Corporation | $77.37 | 2021-2025 | Lithovue |
| Alnylam Pharmaceuticals INC. | $59.44 | 2023 | Amvuttra |
| Janssen Pharmaceuticals, INC | $46.98 | 2023 | Xarelto |
| Ucb, INC. | $37.63 | 2023 | Briviact |
| Abbvie INC. | $37.33 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.29 | 2023 | Xifaxan |
| Adamas Pharmaceuticals, INC. | $23.61 | 2020 | |
| Upsher-Smith Laboratories LLC | $21.07 | 2020 | |
| Merck Sharp & Dohme LLC | $19.54 | 2024 | Zerbaxa |
| Neurocrine Biosciences, INC. | $14.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.14 | 2019 | |
| Daxor Corporation | $11.04 | 2023 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.